Literature DB >> 19744986

Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis--authors' response.

Won-Jung Koh1, Tae Sun Shim.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19744986     DOI： 10.1093/jac/dkp344

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  3 in total

1.  Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480.

Authors:  J W C Alffenaar; T van der Laan; S Simons; T S van der Werf; P J van de Kasteele; H de Neeling; D van Soolingen
Journal:  Antimicrob Agents Chemother       Date:  2011-01-03       Impact factor: 5.191

2.  Linezolid for drug-resistant pulmonary tuberculosis.

Authors:  Bhagteshwar Singh; Derek Cocker; Hannah Ryan; Derek J Sloan
Journal:  Cochrane Database Syst Rev       Date:  2019-03-20

3.  Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation.

Authors:  James Millard; Henry Pertinez; Laura Bonnett; Eva Maria Hodel; Véronique Dartois; John L Johnson; Maxine Caws; Simon Tiberi; Mathieu Bolhuis; Jan-Willem C Alffenaar; Geraint Davies; Derek J Sloan
Journal:  J Antimicrob Chemother       Date:  2018-07-01       Impact factor: 5.790
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.